Clinical toxicities of nanocarrier systems

  • Vega-Villa K
  • Takemoto J
  • Yáñez J
 et al. 
  • 182

    Readers

    Mendeley users who have this article in their library.
  • 151

    Citations

    Citations of this article.

Abstract

Toxicity of nanocarrier systems involves physiological, physicochemical, and molecular considerations. Nanoparticle exposures through the skin, the respiratory tract, the gastrointestinal tract and the lymphatics have been described. Nanocarrier systems may induce cytotoxicity and/or genotoxicity, whereas their antigenicity is still not well understood. Nanocarrier may alter the physicochemical properties of xenobiotics resulting in pharmaceutical changes in stability, solubility, and pharmacokinetic disposition. In particular, nanocarriers may reduce toxicity of hydrophobic cancer drugs that are solubilized. Nano regulation is still undergoing major changes to encompass environmental, health, and safety issues. The rapid commercialization of nanotechnology requires thoughtful environmental, health and safety research, meaningful, and an open discussion of broader societal impacts, and urgent toxicological oversight action. © 2008 Elsevier B.V. All rights reserved.

Author-supplied keywords

  • Dendrimer
  • Nanocarrier
  • Nanomedicine
  • Nanoparticle
  • Nanopharmaceutics
  • Nanosphere
  • Polymeric micelles
  • Toxicity

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free